Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tangzu granule for high-risk diabetic foot
ChiCTR2200062930Phase 3Not yet recruiting
- Sponsor
- Hospital of Chengdu University of Traditional Chinese Medicine
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Tangzu Granule in diabetic foot syndrome and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hospital of Chengdu University of Traditional Chinese Medicine. Primary endpoints: Nerve conduction velocity, Local symptom scale and 2 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
Tangzu Granule
03
Conditions
diabetic foot syndrometype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200062930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062930.